DK1294876T3 - EV-VEGF-nukleinsyrer og -polypeptider samt fremgangsmåder til deres benyttelse - Google Patents

EV-VEGF-nukleinsyrer og -polypeptider samt fremgangsmåder til deres benyttelse

Info

Publication number
DK1294876T3
DK1294876T3 DK01946701T DK01946701T DK1294876T3 DK 1294876 T3 DK1294876 T3 DK 1294876T3 DK 01946701 T DK01946701 T DK 01946701T DK 01946701 T DK01946701 T DK 01946701T DK 1294876 T3 DK1294876 T3 DK 1294876T3
Authority
DK
Denmark
Prior art keywords
polypeptides
methods
present
vegf
well
Prior art date
Application number
DK01946701T
Other languages
English (en)
Inventor
Napoleone Ferrara
William I Wood
Colin Watanabe
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2000/032678 external-priority patent/WO2001040466A2/en
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DK1294876T3 publication Critical patent/DK1294876T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/515—Angiogenesic factors; Angiogenin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
DK01946701T 2000-06-23 2001-06-22 EV-VEGF-nukleinsyrer og -polypeptider samt fremgangsmåder til deres benyttelse DK1294876T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21363700P 2000-06-23 2000-06-23
US23097800P 2000-09-07 2000-09-07
PCT/US2000/032678 WO2001040466A2 (en) 1999-12-01 2000-12-01 Secreted and transmembrane polypeptides and nucleic acids encoding the same
PCT/US2001/020116 WO2002000711A2 (en) 2000-06-23 2001-06-22 Ev-vegf nucleic acids and polypeptides and methods of use

Publications (1)

Publication Number Publication Date
DK1294876T3 true DK1294876T3 (da) 2009-06-02

Family

ID=26908256

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01946701T DK1294876T3 (da) 2000-06-23 2001-06-22 EV-VEGF-nukleinsyrer og -polypeptider samt fremgangsmåder til deres benyttelse

Country Status (13)

Country Link
US (4) US20020172678A1 (da)
EP (2) EP2075334B1 (da)
JP (1) JP5081361B2 (da)
KR (1) KR100871735B1 (da)
CN (2) CN101269214B (da)
AT (1) ATE424458T1 (da)
AU (3) AU6871401A (da)
CA (1) CA2412612C (da)
DE (1) DE60137847D1 (da)
DK (1) DK1294876T3 (da)
ES (1) ES2323569T3 (da)
MX (1) MXPA03000150A (da)
WO (1) WO2002000711A2 (da)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6956108B2 (en) * 1997-06-16 2005-10-18 Genentech, Inc. PRO1184 antibodies
US7264801B2 (en) * 1998-08-11 2007-09-04 Genentech, Inc. EG-VEGF nucleic acids and polypeptides and method of use
US20020172678A1 (en) * 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
US6485938B1 (en) * 1999-11-16 2002-11-26 Zymogenetics, Inc. Nucleic acid molecules that encodes human Zven1
CA2427800A1 (en) 2000-11-03 2002-05-10 The Regents Of The University Of California Prokineticin polypeptides, related compositions and methods
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
AU2002319402B2 (en) * 2001-06-28 2008-09-11 Domantis Limited Dual-specific ligand and its use
BR0212070A (pt) 2001-08-29 2004-09-28 Genentech Inc ácidos nucléicos e polipeptìdeos bv8 com atividade mitogênica
US7498414B2 (en) * 2002-03-04 2009-03-03 Imclone Systems Incorporated Human antibodies specific to KDR and uses thereof
WO2003088904A2 (en) * 2002-04-15 2003-10-30 The Regents Of The University Of California Screening and therapeutic methods for treating circadian rhythm disorders
DE10229379A1 (de) * 2002-06-26 2004-01-29 Schering Ag EG-VEGF Rezeptor Antagonisten
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
EP1600459A3 (en) * 2002-06-28 2005-12-07 Domantis Limited Ligand
CA2500962A1 (en) * 2002-10-07 2004-04-15 Zymogenetics, Inc. Uses of human zven proteins and polynucleotides
JP2006523090A (ja) * 2002-12-27 2006-10-12 ドマンティス リミテッド リガンドに、そしてリガンド受容体に特異的な二重特異性単一ドメイン抗体
WO2004065419A1 (ja) * 2003-01-22 2004-08-05 Takeda Pharmaceutical Company Limited 抗体およびその用途
AU2004219592C1 (en) * 2003-03-12 2011-02-24 Genentech, Inc. Use of Bv8 and/or EG-VEGF to promote hematopoiesis
GB0320238D0 (en) 2003-08-29 2003-10-01 Medical Res Council Treatment of disease
EP1924603A2 (en) * 2005-09-13 2008-05-28 Zymogenetics, Inc. Prok2 antagonists and methods of use
CN101454344A (zh) * 2005-12-01 2009-06-10 杜门蒂斯有限公司 与白细胞介素-1受体1型结合的非竞争性域抗体形式
KR100781753B1 (ko) * 2006-05-24 2007-12-04 연세대학교 산학협력단 Ｄｋｋ2를 포함하는 혈관신생을 촉진시키는 방법
WO2008014547A1 (en) * 2006-07-31 2008-02-07 David Le Couteur Cells genetically modified to express markers of fenestration and uses thereof
NZ580530A (en) * 2007-06-06 2012-04-27 Domantis Ltd Anti vegf polypeptides, antibody variable domains and antagonists
CN112858672A (zh) * 2013-01-30 2021-05-28 弗拉芒区生物技术研究所 用于筛选和药物发现目的的新型嵌合多肽
WO2014201283A1 (en) * 2013-06-12 2014-12-18 The Regents Of The University Of California Methods for protecting ovarian function
JP2015127307A (ja) * 2013-12-27 2015-07-09 国立大学法人福井大学 抗ｐｒｏｋ１抗体による大腸癌の治療
JP6320040B2 (ja) * 2013-12-27 2018-05-09 国立大学法人福井大学 抗ｐｒｏｋ１抗体及び抗ｖｅｇｆ抗体併用による大腸癌の治療
WO2018111913A1 (en) * 2016-12-12 2018-06-21 Gi Dynamics, Inc. Methods for assessing treatment with a gastrointestinal implant
RU2662944C1 (ru) * 2017-02-17 2018-07-31 Общество с ограниченной ответственностью "Группа развития "АПЕКС" Средство для лечения состояний человеческого организма, связанных с уменьшением уровня экспрессии гена prok 1 и/или уменьшением количества белка прокинетицина 1 на основе генно-терапевтических субстанций с геном prok 1, способ получения и использования
US11793889B2 (en) 2018-09-24 2023-10-24 Kinase Pharma Inc. Methods for selective kinase inhibition by endogenously produced antagonists of one or more kinases
CN111621466B (zh) * 2020-06-09 2020-12-29 首都医科大学附属北京朝阳医院 一种肺动脉组织单细胞悬液的制备方法及应用

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4943529A (en) 1982-05-19 1990-07-24 Gist-Brocades Nv Kluyveromyces as a host strain
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
AU3145184A (en) 1983-08-16 1985-02-21 Zymogenetics Inc. High expression of foreign genes in schizosaccharomyces pombe
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4946783A (en) 1987-01-30 1990-08-07 President And Fellows Of Harvard College Periplasmic protease mutants of Escherichia coli
US5010182A (en) 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
IL87737A (en) 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
DE3850542T2 (de) 1987-09-23 1994-11-24 Bristol Myers Squibb Co Antikörper-Heterokonjugate zur Töting von HIV-infizierten Zellen.
GB8724885D0 (en) 1987-10-23 1987-11-25 Binns M M Fowlpox virus promotors
KR0154872B1 (ko) 1987-12-21 1998-10-15 로버트 에이. 아미테이지 발아하는 식물종자의 아크로박테리움 매개된 형질전환
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5240848A (en) 1988-11-21 1993-08-31 Monsanto Company Dna sequences encoding human vascular permeability factor having 189 amino acids
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5009772A (en) 1989-02-27 1991-04-23 Kerr-Mcgee Corporation Solvent extraction process
DK0462145T3 (da) 1989-03-07 1994-08-08 Genentech Inc Covalente konjugater mellem lipid og oligonucleotid
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
ATE144281T1 (de) 1989-04-28 1996-11-15 Rhein Biotech Proz & Prod Gmbh Hefezellen der gattung-schwanniomyces
EP0471796A4 (en) 1989-05-10 1993-05-05 Sloan Kettering Institute For Cancer Research Stably transformed eucaryotic cells comprising a foreign transcribable dna under the control of a pol iii promoter
US5332671A (en) 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0479909B1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
FR2649120B1 (fr) 1989-06-30 1994-01-28 Cayla Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede
WO1991004753A1 (en) 1989-10-02 1991-04-18 Cetus Corporation Conjugates of antisense oligonucleotides and therapeutic uses thereof
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
KR920702409A (ko) 1989-10-24 1992-09-04 원본미기재 새로운 결합을 갖는 올리고뉴클레오티드 유사체
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5386023A (en) 1990-07-27 1995-01-31 Isis Pharmaceuticals Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
US5185450A (en) 1991-02-19 1993-02-09 University Of South Florida Tetrazolium compounds for cell viability assays
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US5644048A (en) 1992-01-10 1997-07-01 Isis Pharmaceuticals, Inc. Process for preparing phosphorothioate oligonucleotides
DE69303494T2 (de) 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
DK0674506T3 (da) 1992-12-02 2001-01-08 Alkermes Inc Væksthormonholdige mikrosfærer med styret frigivelse
JP2879303B2 (ja) 1993-01-14 1999-04-05 佑 本庶 ｃＤＮＡライブラリーの作製方法、および新規なポリペプチドとそれをコードするＤＮＡ
US5531697A (en) 1994-04-15 1996-07-02 Sims Deltec, Inc. Systems and methods for cassette identification for drug pumps
US5637684A (en) 1994-02-23 1997-06-10 Isis Pharmaceuticals, Inc. Phosphoramidate and phosphorothioamidate oligomeric compounds
WO2000053753A2 (en) * 1999-03-08 2000-09-14 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
DE69519382T3 (de) 1994-09-09 2008-09-18 Takeda Pharmaceutical Co. Ltd. Zubereitung mit verzögerter freigabe eines metallsalz eines peptids
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
WO1996040072A2 (en) 1995-06-07 1996-12-19 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of human growth hormone
ZA965368B (en) 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
US5707829A (en) 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby
US6458939B1 (en) 1996-03-15 2002-10-01 Millennium Pharmaceuticals, Inc. Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation
US5858682A (en) 1996-08-02 1999-01-12 Pharmingen E2A/pbx1 fusion protein specific monoclonal antibodies
US6013780A (en) 1996-09-06 2000-01-11 Technion Research & Development Co. Ltd. VEGF145 expression vectors
US5824504A (en) 1996-09-26 1998-10-20 Elshourbagy; Nabil A. Human 7-transmembrane receptor and DNA
WO2000075327A1 (en) * 1999-06-02 2000-12-14 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
WO1999063088A2 (en) 1998-06-02 1999-12-09 Genentech, Inc. Membrane-bound proteins and nucleic acids encoding the same
ATE244579T1 (de) 1997-01-22 2003-07-15 Univ Texas Verfahren und zusammensetzungen des gewebefaktors zur koagulation und behandlung von tumoren
CA2283299A1 (en) 1997-03-07 1998-09-11 Human Genome Sciences, Inc. 186 human secreted proteins
AU6777298A (en) 1997-03-25 1998-10-20 Genetics Institute Inc. Secreted proteins and polynucleotides encoding them
US6956108B2 (en) * 1997-06-16 2005-10-18 Genentech, Inc. PRO1184 antibodies
CA2296287A1 (en) 1997-08-01 1999-02-11 Genset 5' ests for secreted proteins expressed in prostate
DE19811194A1 (de) 1998-03-10 1999-09-16 Metagen Gesellschaft Fuer Genomforschung Mbh Menschliche Nukleinsäuresequenzen aus Prostatagewebe
DE19817557A1 (de) 1998-04-09 1999-10-21 Metagen Gesellschaft Fuer Genomforschung Mbh Menschliche Nukleinsäuresequenzen aus Ovartumorgewebe
JPH11332571A (ja) 1998-05-29 1999-12-07 Taisho Pharmaceut Co Ltd 新規遺伝子とそれにコードされる蛋白質
WO2000008145A2 (en) 1998-08-03 2000-02-17 Novartis Ag Novel genes in control of hematopoiesis
US7264801B2 (en) * 1998-08-11 2007-09-04 Genentech, Inc. EG-VEGF nucleic acids and polypeptides and method of use
US20020172678A1 (en) * 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
CA2296792A1 (en) 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
WO2000052022A1 (en) * 1999-03-01 2000-09-08 Millennium Pharmaceuticals, Inc. Secreted proteins and nucleic acids encoding them
JP2002543840A (ja) 1999-05-19 2002-12-24 インサイト・ゲノミックス・インコーポレイテッド 細胞外シグナル伝達分子
AU3774300A (en) * 1999-06-02 2000-12-18 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1230362A2 (en) * 1999-11-16 2002-08-14 ZymoGenetics, Inc. Human zven proteins
US6485938B1 (en) * 1999-11-16 2002-11-26 Zymogenetics, Inc. Nucleic acid molecules that encodes human Zven1
EP1666494A1 (en) * 1999-12-01 2006-06-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2399776A1 (en) 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides
AU2004219592C1 (en) * 2003-03-12 2011-02-24 Genentech, Inc. Use of Bv8 and/or EG-VEGF to promote hematopoiesis

Also Published As

Publication number Publication date
WO2002000711A2 (en) 2002-01-03
KR20030011104A (ko) 2003-02-06
CN101269214A (zh) 2008-09-24
US7727536B2 (en) 2010-06-01
US8557238B2 (en) 2013-10-15
EP2075334B1 (en) 2013-11-20
AU2006252241A1 (en) 2007-01-25
HK1059452A1 (en) 2004-07-02
JP2004511432A (ja) 2004-04-15
KR100871735B1 (ko) 2008-12-03
ES2323569T3 (es) 2009-07-21
ATE424458T1 (de) 2009-03-15
US20070122412A1 (en) 2007-05-31
CA2412612A1 (en) 2002-01-03
EP2075334A1 (en) 2009-07-01
AU2006252241B2 (en) 2010-03-04
CA2412612C (en) 2013-04-30
US20050064522A1 (en) 2005-03-24
CN1449445A (zh) 2003-10-15
US20020172678A1 (en) 2002-11-21
MXPA03000150A (es) 2003-09-22
AU6871401A (en) 2002-01-08
AU2001268714B2 (en) 2006-09-21
US20100254999A1 (en) 2010-10-07
CN1449445B (zh) 2012-07-18
EP1294876B1 (en) 2009-03-04
EP1294876A2 (en) 2003-03-26
CN101269214B (zh) 2013-09-04
JP5081361B2 (ja) 2012-11-28
DE60137847D1 (de) 2009-04-16
HK1132298A1 (en) 2010-02-19
WO2002000711A3 (en) 2002-06-20
US7446168B2 (en) 2008-11-04

Similar Documents

Publication Publication Date Title
AU6871401A (en) Ev-vegf nucleic acids and polypeptides and methods of use
ATE519847T1 (de) Il-17-homologe polypeptide und ihre therapeutische verwendung
ATE447583T1 (de) Polypeptide und dafür kodierende nukleinsäure
CY1106885T1 (el) Θεραπευτικες χρησεις il-17-ομολογων πολυπεπτιδιων
ATE478145T1 (de) Sekretierte und transmembran polypeptide und dafür kodierende nukleinsäuren
PT1169442E (pt) Polipeptidos segregados e transmembranares e acidos nucleicos que os codificam
DE69939227D1 (de) Menschliches A33-Antigen-ähnliches Protein und dafür kodierende Nukleinsäure
ATE380864T1 (de) Menschliches prostasin-ähnliches protein und dafür kodierende nukleinsäure
DE69926415D1 (de) Sekretiertes Polypeptide und dafür kodierende Nukleinsäuren
DK1300417T3 (da) Secerneret og transmembrant polypeptid og nucleinsyre kodende derfor
DE69827532D1 (de) Polypeptide und dafür kodierende Nukleinsäure
ATE405590T1 (de) Menschliches hcar-ähnliches protein und dafür kodierende nukleinsäure
ATE404585T1 (de) Menschliches synaptogyrin-ähnliches protein und dafür kodierende nukleinsäure
DE60038986D1 (de) Ausgeschiedene und Transmembranpolypeptide und dafür kodierende Nukleinsäure
DK1191101T3 (da) PRO241 polypeptider og nucleinsyre kodende herfor
ATE447026T1 (de) Ausgeschiedene und transmembrane polypeptide und dafür kodierende nukleinsäure
ATE363537T1 (de) Ausgeschiedene und transmembranpolypeptide und dafür kodierende nukleinsäure
ATE447614T1 (de) Menschliches suppressor von fused
DE69829417D1 (de) Polypeptide und dafür kodierende Nukleinsäure